• 1
    Esmon CT. The protein C pathway. Crit Care Med 2000; 28(Suppl.): S448.
  • 2
    Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993; 92: 200312.
  • 3
    Espana F, Zuazu I, Vicente V, Estelles A, Marco P, Aznar J. Quantification of circulating activated protein C in human plasma by immunoassays-Enzyme levels are proportional to total protein C levels. Thromb Haemost 1996; 75: 5661.
  • 4
    Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: part 1. Thromb Haemost 1996; 76: 65162.
  • 5
    Norlund L, Zoller B, Öhlin A-K. A novel thrombomodulin gene mutation in a patient suffering from sagittal sinus thrombosis. Thromb Haemost 1997; 78: 11646.
  • 6
    Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J, the EMET Group. Increased risk of venous thrombosis in carriers of natural anticoagulant deficiencies. Results of the family studies of the Spanish Multicenter Study on Thrombophilia (EMET study). Blood Coagul Fibrinol 1998; 9: 718.
  • 7
    Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr., Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 281721.
  • 8
    Norlund L, Holm J, Zoller B, Öhlin A-K. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction. Thromb Haemost 1997; 77: 24851.
  • 9
    Doggen CJM, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 103741.
  • 10
    Linde-Zwirble WT, Angus DC, Carcillo J. Age-specific incidence and outcome of sepsis in the US. Crit Care Med 1999; 27: A33.
  • 11
    Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon. J Clin Invest 1987; 79: 91825.
  • 12
    Taylor F, Chang A, Ferrell G, Mather T, Catlett R, Blick K, Esmon CT. C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991; 78: 35763.
  • 13
    Nystedt S, Ramakrishnan V, Sundelin J. The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells: comparison with the thrombin receptor. J Biol Chem 1996; 271: 149105.
  • 14
    Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986; 68: 121823.
  • 15
    De Fouw NJ, Van Hinsbergh VW, De Jong YF, Haverkate F, Bertina RM. The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells. Thromb Haemost 1987; 57: 17682.
  • 16
    Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276: 1556770.
  • 17
    Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 1994; 153: 366472.
  • 18
    Grinnell BW, Hermann RB, Yan SB. Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide. Glycobiology 1994; 4: 2216.
  • 19
    Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199203.
  • 20
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. New Engl J Med 2001; 344: 699709.
  • 21
    Fisher CJ, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000; 28: S49S56.
  • 22
    Powars DR, Rogers ZR, Patch MJ, McGehee WG, Francis RB. Purpura fulminans in meningococcemia: association with acquired deficiencies of proteins C and S. New Engl J Med 1987; 317: 5714.
  • 23
    Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8: 558892.
  • 24
    Fukudome K, Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 2648691.
  • 25
    Xu J, Qu D, Esmon NL, Heit JA, Griffin JH. Metalloproteolytic release of endothelial cell protein C receptor. J Biol Chem 1999; 275: 603844.
  • 26
    Deguchi H, Fernández JA, Pabinger I, Heit JA, Griffin JH. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulatn protein C pathway. Blood 2001; 97: 190714.
  • 27
    Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79: 23408.
  • 28
    Esmon CT, Esmon NL, Le Bonniec BF, Johnson AE. Protein C activation. Methods Enzymol 1993; 222: 35985.
  • 29
    Rezaie AR, Esmon CT. The function of calcium in protein C activation by thrombin and the thrombin-thrombomodulin complex can be distinguished by mutational analysis of protein C derivatives. J Biol Chem 1992; 267: 261049.
  • 30
    Stearns DJ, Kurosawa S, Sims PJ, Esmon NL, Esmon CT. The interaction of a Ca2+ dependent monoclonal antibody with the protein C activation peptide region: evidence for obligatory Ca2+ binding to both antigen and antibody. J Biol Chem 1988; 263: 82632.
  • 31
    Eli Lilly. Briefing document for XIGRIS for the treatment of severe sepsis. FDA anti-infective drugs advisory committee, 12 September 2001: 86-2001. http:
  • 32
    Orthner CL, Kolen B, Drohan WN. A sensitive and facile assay for the measurement of activated protein C activity levels in vivo. Thromb Haemost 1993; 69: 4417.
  • 33
    Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, Laszik Z, Esmon CT, Heyderman RS. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. New Engl J Med 2001; 345: 40816.
  • 34
    Pellequer JL, Gale AJ, Getzoff ED, Griffin JH. Three-dimensional model of coagulation factor Va bound to activated protein C. Thromb Haemost 2000; 84: 84957.
  • 35
    Mather T, Oganessyan V, Hof P, Huber R, Foundling S, Esmon C, Bode W. The 2.8 Å crystal structure of Gla-domainless activated protein C. EMBO J 1996; 15: 682231.
  • 36
    Perera L, Foley C, Darden TA, Stafford D, Mather T, Esmon CT, Pedersen LG. Modeling zymogen protein C. Biophys J 2000; 79: 292543.
  • 37
    Laszik ZG, Zhou XJ, Ferrell GL, Silva FG, Esmon CT. Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol 2001; 159: 797802.
  • 38
    Ireland H, Kunz G, Kyriakoulis K, Stubbs PJ, Lane DA. Thrombomodulin gene mutations in myocardial infarction. Circulation 1997; 96: 158.
  • 39
    Aso Y, Fujiwara Y, Tayama K, Takanashi K, Inukai T, Takemura Y. Relationship between plasma soluble thrombomodulin levels and insulin resistance syndrome in type 2 diabetes: a comparison with von Willebrand factor. Exp Clin Endocrinol Diabetes 2001; 109: 2106.
  • 40
    Boehme MWJ, Schmitt WH, Youinou P, Stremmel WR, Gross WL. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med 1996; 101: 38794.